2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by repres
about
Molecular Properties of Red Wine Compounds and Cardiometabolic BenefitsThe prognostic effect of cardiac rehabilitation in the era of acute revascularisation and statin therapy: A systematic review and meta-analysis of randomized and non-randomized studies - The Cardiac Rehabilitation Outcome Study (CROS)Effects of Aspirin on Endothelial Function and HypertensionOmega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemiaRetargeting the management of hypercholesterolemia - focus on evolocumabEffect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease: protocol for an overview of systematic reviewsMendelian randomization in cardiometabolic disease: challenges in evaluating causality.Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.Management standards for stable coronary artery disease in India.Management Protocols of stable coronary artery disease in India: Executive summary.Clustering of cardiovascular risk factors and carotid intima-media thickness: The USE-IMT study[National disease management guidelines (NVL) for chronic CAD : What is new, what is particularly important?].The polypill approach - An innovative strategy to improve cardiovascular health in Europe.Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis.Commentary: Mendelian randomization-inspired causal inference in the absence of genetic data.Alcohol consumption, sinus tachycardia, and cardiac arrhythmias at the Munich Octoberfest: results from the Munich Beer Related Electrocardiogram Workup Study (MunichBREW).Different Types of Physical Activity and Fitness and Health in Adults: An 18-Year Longitudinal Study.Anti-Apolipoprotein A-1 IgG Predict All-Cause Mortality and Are Associated with Fc Receptor-Like 3 Polymorphisms.Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.Cardiovascular risk assessment in patients with diabetes.Association between hemoglobin glycation index with insulin resistance and carotid atherosclerosis in non-diabetic individuals.Prevalence, Awareness, Treatment, and Control of Hypertension among Chinese First-Generation Migrants and Italians in Prato, Italy: The CHIP Study.Can pulses play a role in improving cardiometabolic health? Evidence from systematic reviews and meta-analysesCurrent guidelines on prevention with a focus on dyslipidemias.Governmental efforts for cardiovascular disease prevention efforts in the Russian Federation.The role of nutraceuticals in the prevention of cardiovascular disease.Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation studyDesign and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.Single-Pill Combination of Perindopril/Indapamide/Amlodipine in Patients with Uncontrolled Hypertension: A Randomized Controlled Trial.Does the presence of cardiovascular disease risk factors or established disease influence the dietary intake of affected adults and their children residing in the same household? A secondary analysis of the Australian Health Survey (2011-2013)Television viewing time among statin users and non-users. The Polish Norwegian Study (PONS)Epidemiology and Management of Atrial Fibrillation and Stroke: Review of Data from Four European Countries.Effectiveness of a physical activity program on cardiovascular disease risk in adult primary health-care users: the "Pas-a-Pas" community intervention trial.Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.Is There a Role for Genomics in the Management of Hypertension?Cardiovascular Risk Stratification and Statin Eligibility Based on the Brazilian vs. North American Guidelines on Blood Cholesterol Management.The Expected Cardiovascular Benefit of Plasma Cholesterol Lowering with or Without LDL-C Targets in Healthy Individuals at Higher Cardiovascular Risk.Diet quality and carotid atherosclerosis in intermediate cardiovascular risk individuals.The associations of cardiorespiratory fitness, adiposity and sports participation with arterial stiffness in youth with chronic diseases or physical disabilities.Risk of post-pregnancy hypertension in women with a history of hypertensive disorders of pregnancy: nationwide cohort study.
P2860
Q26741941-D9F02E34-7FDA-4526-B731-C548ABA98FA9Q28071340-BF582FF1-347D-433D-8720-54301D0270E1Q28071501-FD734926-BA5D-4131-B36A-ED1CB98648F5Q28076399-A0A2262A-E707-4671-B17E-9BA93EAA7CA8Q28077289-FB293276-51E1-4F8E-B0E4-3AD7C752BF4FQ29247935-E3E287FE-38DA-41ED-8D7C-3D2C19FBBFFAQ30234302-73BE9F0B-57BB-475C-9D75-C314B9D7745AQ30235416-91B4EA23-E04A-425A-9C17-EAABD01065DFQ30239853-2861F26B-94DE-42AA-90FD-680B18349A5AQ30240155-5C1D0DEC-9440-4E09-A2CE-3C808E427CFEQ30252911-4065904F-0EC7-4CC8-9C65-DCFAD3DE0DD8Q30313892-E4EFF1AA-9302-48F9-B7E3-62F49158363FQ30398270-FA9209F6-3CF5-4829-8F78-13B36FDC140AQ31126960-58239CEB-9B2F-4F8E-9D7A-12A1CAE5EEBEQ31151462-12C755B6-8568-4B44-86E7-378341FAF886Q33454258-4A4BA9AA-1E3B-4AAD-8075-29447618D702Q33561464-AD1A801A-E74D-4DC9-AA0E-A125450D848FQ33573479-71E79243-606B-4A96-A720-7194339645E4Q33581084-3B2B613D-53A9-4EBD-B7A0-178D9079095DQ33582582-77B276C1-89AB-42AA-8D75-F0D57FFECB35Q33584606-E9C115C5-B3DD-486A-9D64-AB1DE4F42E29Q33607997-9A53D002-CA63-4041-8A01-A37070A445EFQ33628677-F6D77004-63A0-4AAA-9A14-4E1852C5194CQ33638988-77BA45A2-6F16-43A8-9E58-00E4F70F09B0Q33638994-0BA40392-12C3-4B5E-8863-460DFFED89ACQ33639005-D4A20B43-877D-4FC7-99C4-53C489E51512Q33647341-3957BDE2-A5E9-4CA5-96EC-9E244F5A5319Q33730396-37250AB7-31C7-4797-B281-46B55C14C740Q33734032-80DFBDB0-50A9-4F52-A38D-728FE139C1CDQ33767833-CC00F934-B346-4E88-A0B9-8647EB8D1D18Q33784301-9CFC30FC-C906-4159-921F-E2B2C03566EBQ33786841-B52A406C-F94A-44EA-91E2-988B3C584BAEQ33802024-3731A53C-EB2A-4EDC-A6D7-B726284D3845Q33808302-8F0640FB-7A9B-4BDE-A149-63A35C5C8500Q33838442-009CA9C7-2B1A-4369-9008-4C19EFA26BB8Q33848763-7F3A8D5B-5330-4452-B2C7-279A985AAD7AQ33848767-28B72384-AB74-4042-BC3D-0242A2E23CD4Q33864219-337A39E0-5766-4703-9EDD-E403DE230E47Q33866006-0EF9DBC9-E508-4BB2-8CA9-3536637DB44BQ33897028-926AA21E-C77D-44FB-B829-53D57A764641
P2860
2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by repres
description
2016 nî lūn-bûn
@nan
2016 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
2016 European Guidelines on ca ...... ractice (constituted by repres
@ast
2016 European Guidelines on ca ...... ractice (constituted by repres
@en
2016 European Guidelines on ca ...... revention in Clinical Practice
@nl
type
label
2016 European Guidelines on ca ...... ractice (constituted by repres
@ast
2016 European Guidelines on ca ...... ractice (constituted by repres
@en
2016 European Guidelines on ca ...... revention in Clinical Practice
@nl
prefLabel
2016 European Guidelines on ca ...... ractice (constituted by repres
@ast
2016 European Guidelines on ca ...... ractice (constituted by repres
@en
2016 European Guidelines on ca ...... revention in Clinical Practice
@nl
P2093
P2860
P50
P356
P1476
2016 European Guidelines on ca ...... ractice (constituted by repres
@en
P2093
Arno W Hoes
Authors/Task Force Members
Bernard Cosyns
Carlos Brotons
Christi Deaton
Christian Albus
Dimitrios J Richter
F D Richard Hobbs
H Bart van der Worp
Herbert Löllgen
P2860
P304
P356
10.1093/EURHEARTJ/EHW106
P50
P577
2016-05-23T00:00:00Z